In terms of mutations, a cross-sectional study demonstrated shorter OS in patients with low-grade gliomas with BRCA1 or BRCA2 mutations.20 In this retrospective study, BRCA2 mutation was a prognostic factor in univariate analysis but not in multivariable analysis. Here, BRCA1 is linked to central nervous system cancer.